The pharmaceutical middlemen who play a role in inflating consumer drug prices escaped additional regulations by state lawmakers, after the Nevada State Legislature failed to pass a bill designed to curb how much profit they can make.

Democratic state Sen. Rochelle Nguyen’s Senate Bill 316 would have established “guardrails” for pharmaceutical benefit managers, such as requiring PBMs to pass along to consumers rebate savings they receive from the drug companies. Nguyen led the legislative effort but a bipartisan group of eight other lawmakers signed on, including Republican state Sen. Jeff Stone, a pharmacist, and Senate Minority Leader Robin Titus, a medical doctor.

The Senate and Assembly passed different versions of SB216, both with broad bipartisan support. Only Democratic st

See Full Page